Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Lipari Mining (N.LML) Announces Q1-2025 Production and Sales Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News UNITY Biotechnology Inc UBX

Healthcare Biotechnology
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms... see more

Recent & Breaking News (NDAQ:UBX)

UNITY Biotechnology's Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye

GlobeNewswire October 11, 2022

UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye

GlobeNewswire October 6, 2022

UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration

GlobeNewswire September 19, 2022

UNITY Biotechnology to Participate in Upcoming Investor Conferences

GlobeNewswire August 31, 2022

UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering

GlobeNewswire August 17, 2022

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

GlobeNewswire August 16, 2022

UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates

GlobeNewswire August 12, 2022

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

GlobeNewswire August 12, 2022

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

GlobeNewswire August 11, 2022

UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

GlobeNewswire July 12, 2022

UNITY Biotechnology Reports Granting of New Employment Inducement Award

GlobeNewswire June 29, 2022

UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

GlobeNewswire May 26, 2022

UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference

GlobeNewswire May 25, 2022

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

GlobeNewswire May 10, 2022

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

GlobeNewswire May 5, 2022

UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting

GlobeNewswire April 21, 2022

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration

GlobeNewswire April 19, 2022

UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

GlobeNewswire April 12, 2022

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

GlobeNewswire March 15, 2022

UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference

GlobeNewswire March 1, 2022